Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alfresa HoldingsARHCF 82 3-1 Month Momentum % is N/A% as of Aug. 10, 2026. GuruFocus rates ARHCF with a GF Score™ of 82/100 and a GF Value™ of $12.24 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 125 Medical Distribution companies, Alfresa Holdings ranks worse than 56% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-10), Alfresa Holdings's 3-1 Month Momentum % is N/A%.
The industry rank for Alfresa Holdings's 3-1 Month Momentum % or its related term are showing as below:
ARHCF's 3-1 Month Momentum % is not ranked *
in the Medical Distribution industry.
Industry Median: -4.99 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Alfresa Holdings 3-1 Month Momentum % Related Terms
ARHCF vs MCK, COR, CAH: 3-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Alfresa Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings 3-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alfresa Holdings (ARHCF) has a 3-1 Month Momentum % of N/A% as of Aug. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alfresa Holdings and its competitors. According to the industry distribution chart, Alfresa Holdings ranks #70 out of 125 companies in the Medical Distribution industry, placing it in the top 56%.
Is Alfresa Holdings' 3-1 Month Momentum % too high?
Alfresa Holdings' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Alfresa Holdings ranks #70 out of 125 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Alfresa Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' 3-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #70 out of 125 companies for 3-1 Month Momentum %. This places Alfresa Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Distribution company?
A good 3-1 Month Momentum % depends on the Medical Distribution industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alfresa Holdings and its competitors. Alfresa Holdings's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ARHCF) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.24, compared to a current price of $14.00 — trading 14.4% above its estimated fair value. The current 3-1 Month Momentum % is N/A%. Alfresa Holdings' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Alfresa Holdings (ARHCF), the current 3-1 Month Momentum % is N/A% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ARHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be overvalued.
The current stock price of $14.00 is trading 14.4% above its estimated GF Value™ of $12.24.
GuruFocus considers Alfresa Holdings to be Modestly Overvalued.
Key valuation signals for ARHCF:
3-1 Month Momentum %: N/A%
GF Value™: $12.24 vs. price of $14.00 (14.4% above fair value)
No single metric tells the full story. See the ARHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
82GF Score
Get the complete analysis for ARHCF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARHCF has been successfully added to your 
